Feasibility of OmnEcoil System for Integrated Endorectal MRI and Transrectal MRI-Targeted Biopsy of the Prostate

Inclusion Criteria:

Males, aged >= 45 years
Willing and able to provide written informed consent, including willingness to undergo MRI-targeted biopsy using OmnEcoil investigational system
Persistently elevated (> 3 ng/mL) or rising prostate specific antigen (PSA) level and/or abnormal digital rectal exam
Prior negative transrectal ultrasound (TRUS) biopsy, or prior TRUS biopsy or transurethral resection of the prostate showing Gleason score =< 6 disease
Received multiparametric prostate MRI within last 6 months prior to study enrollment with images available on Oregon Health and Science University (OHSU) image viewing system for review
Must have at least one high-value biopsy target (i.e., score of 4 or 5 as categorized by Prostate Imaging and Reporting and Data System [PI-RADS] version 2.1) present on multiparametric MRI as evaluated by study radiologists
Eastern Cooperative Group (ECOG) performance score 0 or 1
Patient able to lie prone in MRI for OmnEcoil biopsy procedure

Considered to be low bleeding risk [per Society for Interventional Radiology], including:

International normalized ratio (INR) >= 1.5, and
Platelets >= 50,000

Exclusion Criteria:

Contraindication to MRI (e.g., severe claustrophobia, intracranial aneurysm clips, intraocular metallic foreign body, and cardiac pacemaker)
Any contraindication to endorectal devices and/or biopsy, including (but not limited to) severe hemorrhoids, anal fissure, recent rectal surgery, or prior abdominoperineal resection
Any bleeding diathesis and/or anti-coagulative therapy that cannot be temporarily reversed
Active infection requiring systemic antibiotic therapy. Participants requiring systemic antibiotics for infection must have completed antibiotic therapy before initiating OmnEcoil imaging/biopsy procedure
Administration of treatment for prostate cancer such as radiation or hormonal therapy prior to MRI-targeted biopsy
Uncontrolled intercurrent illness that would substantially increase risk of incurring adverse events (AEs), confound results, or compromise the ability of the patient to give written informed consent
Subjects unwilling to accept a blood transfusion
Previous use of an endorectal coil for diagnostic prostate MRI within < 8 weeks prior to OmnEcoil imaging/biopsy procedure